Acuvax Limited announced audited consolidated earnings results for the half year ended December 31, 2012. For the year, total revenue was AUD 10,845, loss from continuing operations before income tax was AUD 237,744 and loss for the period attributable to members of the parent company was AUD 226,704 or AUD 0.010 per diluted share against total revenue of AUD 23,608, loss from continuing operations before income tax of AUD 319,618 and loss for the period attributable to members of the parent company of AUD 319,838 or AUD 0.015 per diluted share for the same period a year ago. Net cash use in operating activities was AUD 216,977 against AUD 341,921 a year ago. Net tangible assets per share was 0.020 cents against 0.039 cents a year ago.

Acuvax Limited announced that the incoming management team includes seasoned biotechnology executives and company builders, Dr. Roger Aston and Mr. Paul Hopper as well as a Scientific Advisory Board that includes several of the inventors. Dr. Aston has held leadership roles with Peptech Ltd, Cambridge Antibody Technology, Clinuvel Ltd, pSivida Corp. and Mayne Pharma Ltd. Mr. Hopper is currently Head of the Life Sciences Desk of US Investment Bank, Cappello Capital Corp, is Executive Chairman of Viralytics Ltd. and a Director of both pSivida Corp. and Immugene Ltd. Both have extensive experience of developing therapeutic drugs, undertaking clinical trials and marketing products. Director elect, Dr. Axel Hoos, will be joining the ACU Board in March 2013. Dr. Hoos, previously Head of Oncology at Glaxo Smithkline brings a wealth of experience in cancer drug development to ACU.

Acuvax Limited announced that they will report first half, 2013 results on Feb 28, 2013